Transgenic Mice Lacking IFNγ or IL-17A
Research on HLA-DR3 transgenic mice lacking IFNγ or IL-17A showed that neither cytokine is required for developing experimental autoimmune encephalomyelitis (EAE). Mice without IFNγ exhibited brain-specific EAE marked by increased IL-17A, while those without IL-17A showed typical spinal cord-targeting EAE. Atypical disease with brain inflammation was noted in double knockout mice. TNFα inhibition helped reduce this atypical disease.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
These findings reveal that specific cytokines play unique roles in EAE, a model for multiple sclerosis, and suggest that targeting TNFα may be beneficial for atypical EAE forms.
What this does not prove
The study did not establish direct applicability to human MS.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-01
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceTNFα promotes brain-predominant EAE independent of IFNγ and IL-17A in HLA-DR3 transgenic mice. ↗DOI: 10.1093/jimmun/vkag268
Supporting passages (4)
publication date2026-10-01
interventionTNFα inhibition
findingsUtilizing HLA-DR3 (DRβ1*0301) transgenic mice lacking IFNγ or IL-17A in experimental autoimmune encephalomyelitis (EAE), a model of MS, we found that neither cytokine is essential for disease induction, although both have distinct roles.
limitationsTitle: TNFα promotes brain-predominant EAE independent of IFNγ and IL-17A in HLA-DR3 transgenic mice.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.